2. Pinkawa M. External beam radiotherapy for prostate cancer. Panminerva Medica. 2010;52(3):195–207.

3. Barchetti F., Panebianco V. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy.BioMed Research International Volume. 2014;1–23.

4. Murphy A.M., Berkman D.S., Desai M., et al. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy.BJUInt. 2010;105(2):176–179.

5. Olsson A.Y., Bjartell A., Lilja H., et al. Expression of Prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. International Journal of Cancer. 2005;113(2):290–297.

6. Cornford P., Bellmunt J., Bolla M., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 2: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017;71(4):630–642. Doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

7. Paller C.J., Antonarakis E.S. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11(1):14–23.

8. Scattoni V., Montorsi F., Picchio M. et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int. 2004;93(5):680–688.

9. Korobkin A.S., Shariya M.A., Ustyuzhanin D.V., Voskanyan G.A., Vinarov A.Z. Diagnostic value of modern techniques of MRI (MRS, DWI, perfusion) in the detection of prostate cancer. Rossiiskii elektronnyi zhurnal luchevoi diagnostiki (Prilozhenie). 2014;3(2):155–56. Russian (Коробкин А.С., Шария М.А., Устюжанин Д.В., Восканян Г.А., Винаров А.З. Диагностическое значение современных методик МРТ (МРС, ДВИ, перфузии) в выявлении рака предстательной железы. Российский электронный журнал лучевой диагностики (Приложение). 2014;3(2):155–56).

10. De Visschere P.J., De Meerleer G.O., Fütterer J.J., Villeirs G.M. Role of MRI in Follow-Up after focal therapy for prostate carcinoma. Am J Roentgenol. 2010;194:1427–1433.

11. Kim J.K., Jang Y.J., Cho G. Multidisciplinary functional MR Imaging for prostate cancer. Korean J Radiol. 2009;10:535–551.

12. Korobkin A.S., Shariya M.A., Voskanyan G.A., Vinarov A.Z. MR-spectroscopy in the diagnosis of prostate cancer. Rossiiskii elektronnyi zhurnal luchevoi diagnostiki (Prilozhenie). 2013;3(2):143–144. Russian (Коробкин А.С., Шария М.А., Восканян Г.А., Винаров А.З. МР-спектроскопия в диагностике рака предстательной железы. Российский электронный журнал лучевой диагностики (Приложение). 2013;3(2):143–144).

13. Nguyen D.P., Giannarini G., Seiler R. et al. Local recurrence after retropubic radical prostatectomy for prostate cancer does not exclusively occur at the anastomotic site. BJU Int. 2013;112(4):243–249.

14. Panebianco V., Barchetti F., Grompone M.D., et al. Magnetic resonance imaging for localization of prostate cancer in thesetting of biochemical recurrence. UrolOncol. 2016;34(7):303–311.

15. Sefrova J., Odrazka K., Paluska P. et al. Magnetic resonance imaging in postprostatectomy radiotherapy planning. Int J RadiatOncolBiolPhys. 2012;82(2):911–918.

16. Lindenberg L., Ahlman M., Turkbey B., et al. Evaluation of Prostate Cancer with PET/MRI. J Nucl Med. 2016;57:111–116.

17. Silverman J.M., Krebs T.L. MRimaging evaluationwith a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. Am J Roentgenol. 1997;168(2):379–385.

18. Panebianco V., Sciarra A., Lisi D. et al. Prostate cancer: 1HMRS-DCEMR at 3T versus

19. Sciarra A., Panebianco V., Salciccia S. et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008;54(3):589–600.

20. Wu L.M., Xu J.R., Gu H. Y. et al. Role ofmagnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. ClinOncol (R CollRadiol). 2013;25(4):252–364.

21. Giannarini G., Nguyen D.P., Thalmann G.N., Thoeny H.C. Diffusion-weighted magnetic resonance imaging detects local recurrence after radical prostatectomy: initial experience. Eur Urol. 2012;61(3):616–620.

22. Kim C.K., Park B.K., Park W., Kim S.S. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging. 2010;35(2):246–252.

23. Kim C.K., Park B.K., Lee H.M. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J MagnReson Imaging. 2009;29:391–397.

24. Panebianco V., Barchetti F., Sciarra A. et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging.Eur J Radiol. 2013;23(6):1745–1752.

25. Moman M.R., van den Berg C.A., Boeken Kruger A.E. et al. Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J RadiatOncolBiolPhys. 2010;76(3):741–746.

26. Arumainayagam N., Kumaar S., Ahmed H.U. et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int. 2010;106:991–997.

27. Roy C., Foudi F., Charton J. et al. Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. Am J Roentgenol. 2013;200(4):361–368.

28. Donati O.F., Jung S.I., Vargas H.A. et al. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: Are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology. 2013;268:440–450.

29. Westphalen A.C., Kurhanewicz J., Cunha R.M.G. et al.T2-weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. IntBraz J Urol. 2009;35(2):171–182.

30. Schiavina R., Ceci F., Borghesi M. et al. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Current Radiopharmaceuticals. 2013;6(2):92–95.

31. Oppenheimer D.C., Weinberg E.P., Hollenberg G.M., Meyers S.P. Multiparametricmagnetic resonance imaging of recurrent prostate cancer. J Clin Imaging Sci. 2016;29:6–18.

32. De Visschere P.J., De Meerleer G.O., Fütterer J.J., Villeirs G.M. Role of MRI in follow-up after focal therapy for prostate carcinoma. Am J Roentgenol. 2010;194(6):1427–1433.

33. Kara T., Akata D., Akyol F. et al. The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings. Diagn Interv Radiol. 2011;17(1):38–43.

34. Panebianco V., Barchetti F., Musio D. et al.Metabolic atrophy and 3T 1H-MR spectroscopy correlation after radiation therapy for prostate cancer. BJU Int. 2014;114(6):852–859.

35. Morgan V.A., Riches S.F., Giles S. et al. Diffusion-weighted MRI for locally recurrent prostate cancer after external beamradiotherapy. Am J Roentgenol. 2012;198(3):596–602.

36. Hamstra D.A., Rehemtulla A., Ross B.D. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J ClinOncol. 2007;25(26):4104–4109.

37. De Souza N.M., Reinsberg S.A., Scurr E.D. et al. Magnetic resonance imaging in prostate cancer the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol. 2007;80(950):90–95.

38. Song I., Kim C.K., Park B.K., Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion weighted MRI at 3 T.Am J Roentgenol. 2010;194(6): 477–482.

39. Liu L., Wu N., Ouyang H., Dai J.R., Wang W.H. Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer. Br J Radiol. 2014;87(1043):20140359. Doi: 10.1259/bjr.20140359.

40. Grant K.B., Agarwal H.K., Shih J.H. et al. Comparison of calculated and acquired high b-value diffusion weighted imaging in prostate cancer. Abdom Imaging. 2015;40(3):578–586.

41. Tamada T., Sone T., Jo Y. et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusionweighted imaging, dynamic contrast-enhanced MRI and T2- weighted imaging in localizing tumors. Am J Roentgenol. 2011;197(2):408–414.

42. Donnelly S.E., Donnelly B.J., Saliken J.C. et al. Prostate cancer: gadolinium-enhanced MR imaging at 3 weeks compared with needle biopsy at 6 months after cryoablation. Radiology 2004;232:830–833.

43. Beresford M.J., Gillatt D., Benson R.J., Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. ClinOncol (R CollRadiol). 2010;22(1):46–55.